Evidence map›Paper›PMID 41383103›Full record

Observational studyThe Journal of clinical endocrinology and metabolism2026

Visceral adipose tissue and liver fat on 17-beta estradiol-dominant gender-affirming hormone therapy: A US-based cohort.

Ria Talathi, Vencel Juhasz, Matilda Delgado, Thiago Quinaglia, Azin Ghamari, Melissa Wang, Iad Alhallak, Sarah Stinebaugh, Sophia Campbell, Sara L Stockman and 9 more

Abstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in The Journal of clinical endocrinology and metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Ria TalathiMetabolism Unit, Division of Endocrinology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.
Vencel JuhaszCardiovascular Imaging Research Center (CIRC), Department of Radiology and Division of Cardiology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.
Matilda DelgadoMetabolism Unit, Division of Endocrinology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.
Thiago QuinagliaCardiovascular Imaging Research Center (CIRC), Department of Radiology and Division of Cardiology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.
Azin GhamariCardiovascular Imaging Research Center (CIRC), Department of Radiology and Division of Cardiology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.
Melissa WangMetabolism Unit, Division of Endocrinology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.
Iad AlhallakMetabolism Unit, Division of Endocrinology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.
Sarah StinebaughMetabolism Unit, Division of Endocrinology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.
Sophia CampbellMetabolism Unit, Division of Endocrinology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.
Sara L StockmanMetabolism Unit, Division of Endocrinology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.
Mustafa A OzturkMetabolism Unit, Division of Endocrinology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.
Sadia M AhmadiBoston University Chobanian & Avedisian School of Medicine, Boston, MA 02118, USA.
Sara E LoobyMetabolism Unit, Division of Endocrinology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.
Hang LeeBiostatistics Center, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.ORCID 0000-0002-3498-236X
Tonia C PoteatDivision of Healthcare in Adult Populations, Duke University School of Nursing, Durham, NC 27710, USA.
Lidia S SzczepaniakMRS Consulting in Biomedical Research, Albuquerque, NM 87112, USA.
Markella V ZanniMetabolism Unit, Division of Endocrinology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.
Tomas G NeilanCardiovascular Imaging Research Center (CIRC), Department of Radiology and Division of Cardiology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.
Mabel ToribioMetabolism Unit, Division of Endocrinology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.ORCID 0000-0002-4153-5568

Funding

NIH/NHLBI 1K23HL147799-01Robert Wood Johnson Foundation
6 · The paper itself

Abstract

contextData on the metabolic effects of contemporaneous gender-affirming hormone therapy (GAHT) are limited.

objectiveTo characterize the metabolic effects of GAHT ie, estradiol with anti-androgen therapy.

designProspective observational study with a 12-month follow-up period.

settingAcademic medical center in greater Boston, Massachusetts, USA.

participantsTwenty-six transgender women and nonbinary individuals with no history of cardiovascular disease or diabetes who were either planning to initiate or who had recently initiated GAHT consisting of 17 beta(β)-estradiol and anti-androgen therapy. INTERVENTION(S): GAHT. MAIN OUTCOME MEASURE(S): The prespecified primary outcome was the change in visceral adipose tissue (VAT). Prespecified secondary outcomes included change in bone density, insulin sensitivity, and intrahepatic triglyceride content (hTG).

resultsMedian age of participants was 26 (20, 30) years. After 12 months, VAT mass and volume did not change. While lumbar, total hip, and femoral bone density increased, insulin sensitivity did not change. hTG decreased over 12 months (median change: -0.2 [-1.3, 0.1]%, P = .03). Total lean body mass and the appendicular lean body mass/height2 decreased (mean change: -0.31 ± 0.38 kg/m2, P = .0003). Systemic triglycerides levels increased, whereas high-density lipoprotein cholesterol and low-density lipoprotein cholesterol, did not change over 12 months. Free testosterone levels at follow-up independently predicted the change in hTG, controlling for estradiol levels, body mass index, and waist-to-hip ratio at follow-up.

conclusionKey indices of metabolic health, such as VAT and insulin sensitivity, did not change after 12 months of GAHT. Appendicular lean body mass/height2, a predictor of sarcopenia, unfavorably decreased, while hTG favorably decreased. Awareness of the metabolic effects of GAHT may lead to the implementation of strategies aimed at mitigating sarcopenia risk.

Indexed as

Androgen AntagonistsEstradiolGender-Affirming ProceduresIntra-Abdominal FatLiverTranssexualismAdultBone DensityCohort StudiesFemaleFollow-Up StudiesHormone Replacement TherapyHumansInsulin ResistanceMaleProspective StudiesAndrogen AntagonistsEstradiolandrogen suppressionbody compositionestradiolgender-affirming hormone therapyhepatic fattransgender women

Identifiers

PMID41383103
PMCPMC13183449

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.